Thymosin Alpha-1 (Thymalfasin): A 28-Residue Immunomodulatory Thymic Peptide

Research summary. Thymosin alpha-1 is a 28-amino-acid immunomodulatory peptide originally isolated from the thymus by Allan Goldstein and colleagues in the 1970s. Its synthetic equivalent, thymalfasin, has been used clinically for decades across more than thirty countries (though not in the United States) as an immunomodulator in chronic hepatitis B and hepatitis C, in immunocompromised vaccine-response contexts, and in adjunctive cancer immunotherapy. Thymosin alpha-1 acts on dendritic-cell and T-cell signalling — predominantly via TLR-engagement-related mechanisms — to support coordinated host-defence and immune-regulation programmes. It drew renewed research attention during the COVID-19 pandemic for its reported effects on immune dysregulation in severe viral illness.

Molecular profile

• Sequence: Ac-Ser-Asp-Ala-Ala-Val-Asp-Thr-Ser-Ser-Glu-Ile-Thr-Thr-Lys-Asp-Leu-Lys-Glu-Lys-Lys-Glu-Val-Val-Glu-Glu-Ala-Glu-Asn (28 residues, N-terminally acetylated)
• Molecular formula: C₁₂₉H₂₁₅N₃₃O₅₅
• Molecular weight: ~3108.3 g/mol
• Class: Immunomodulatory thymic peptide (proteolytic fragment of prothymosin alpha)
• Synonyms: Thymalfasin; Zadaxin (brand); Tα1
• Approval status: Approved in 35+ countries for chronic hepatitis B and chronic hepatitis C (often in combination with interferon-α); not FDA-approved in the United States

Mechanism of action

Thymosin alpha-1 acts as a multi-pathway immunomodulator rather than as a stimulant of any single immune lineage:

• TLR-engagement-related signalling. Reported across in-vitro work; thymosin alpha-1 has been described as engaging TLR2 and TLR9 pathways on dendritic cells and other innate-immune cell types, with downstream effects on cytokine production and T-cell priming.
• Dendritic-cell maturation. Reported effects on dendritic-cell phenotype and antigen-presentation capacity, supporting downstream T-cell activation.
• T-cell function. Reported effects on T-cell maturation, on the Th1/Th2 cytokine balance, and on regulatory T-cell populations.
• NK-cell activity. Reported increases in natural-killer-cell cytotoxic activity in some research models, contributing to the reported antiviral and anti-tumour effects.
• Restoration rather than stimulation. The published mechanistic framing emphasises restoration of normal immune function in dysregulated or immunocompromised states, rather than supraphysiological immune activation.

Preclinical and clinical research highlights

Chronic hepatitis B. Multiple Phase 3 and post-marketing studies have reported that thymosin alpha-1, particularly in combination with interferon-α, is associated with improved virological-response and seroconversion endpoints in chronic hepatitis B.

Chronic hepatitis C. Similar combination-therapy data have reported improved sustained-virological-response rates with thymosin alpha-1 plus interferon-α versus interferon-α monotherapy, particularly in interferon-resistant populations.

Adjuvant cancer immunotherapy. Thymosin alpha-1 has been studied across multiple cancer types (melanoma, hepatocellular carcinoma, non-small-cell lung cancer) as an adjunct to chemotherapy or immune-checkpoint approaches, with reported improvements in immune-recovery and survival endpoints in some trials.

Vaccine response. Reported effects in immunocompromised populations (haemodialysis, elderly) include improved antibody-response rates to influenza and hepatitis-B vaccinations.

COVID-19 research. Observational studies during the COVID-19 pandemic — predominantly from China and Italy — reported that thymosin alpha-1 administration was associated with reduced mortality in severe cases, attributed to its reported effects on immune-dysregulation endpoints. These observational data are not the basis for any approved indication.

Sepsis and critical illness. Thymosin alpha-1 has been studied in sepsis-related immune dysfunction, with reported improvements in immune-recovery and short-term-mortality endpoints in some randomised trials.

Current research status

Thymosin alpha-1 / thymalfasin is approved in 35+ countries (notably Italy, China, and others) as a prescription immunomodulator, primarily for chronic hepatitis B and C. It is not FDA-approved in the United States. Research-grade thymosin alpha-1 is supplied for laboratory use only.

For research-supplier contexts, thymosin alpha-1 is supplied as a research-grade investigational peptide and is not intended for self-administration.

Key takeaways for researchers

• Thymosin alpha-1 is a 28-residue immunomodulatory thymic peptide with decades of published clinical research.
• The mechanism is multi-pathway immunomodulation via TLR-engagement-related signalling, dendritic-cell maturation support, and Th1/Th2 balance modulation.
• It is approved in 35+ countries for chronic hepatitis B and C; it is not FDA-approved in the United States.
• Reported applications include chronic hepatitis, adjuvant cancer immunotherapy, vaccine-response support in immunocompromised populations, sepsis, and (observationally) severe COVID-19.
• Research-grade thymosin alpha-1 is for laboratory use only.

References

1. Goldstein AL, Low TL, McAdoo M, McClure J, Thurman GB, Rossio J, Lai CY, Chang D, Wang SS, Harvey C, Ramel AH, Meienhofer J. Thymosin alpha1: isolation and sequence analysis of an immunologically active thymic polypeptide. Proc Natl Acad Sci USA. 1977;74(2):725–729.
2. Camerini R, Garaci E. Historical review of thymosin α1 in infectious diseases. Expert Opin Biol Ther. 2015;15 Suppl 1:S117–127.

---

This article is provided for educational and research purposes only. Thymosin alpha-1 is a research peptide. It is not an FDA-approved drug in the United States and is not intended for human consumption, diagnosis, treatment, cure, or prevention of any disease or condition. All work involving this peptide should be conducted by qualified personnel within an appropriate research setting and in compliance with applicable institutional and regulatory requirements.